Fulgent Genetics (FLGT) announced it has been awarded a five-year contract by the U.S. Department of Veterans Affairs, or VA, to provide hereditary cancer, pharmacogenetic and other genetic testing to Veterans. Fulgent has been periodically providing genetic testing services to the members of the VA since 2017. The award is for up to $99M over five years, including both hereditary cancer testing and pharmacogenetic testing.
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter